Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) EBIT: 2020-2025

Historic EBIT for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to -$29.4 million.

  • Caribou Biosciences' EBIT rose 23.11% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.8 million, marking a year-over-year increase of 3.88%. This contributed to the annual value of -$166.6 million for FY2024, which is 43.56% down from last year.
  • As of Q3 2025, Caribou Biosciences' EBIT stood at -$29.4 million, which was up 38.21% from -$47.6 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' EBIT registered a high of -$13.2 million during Q1 2021, and its lowest value of -$47.6 million during Q2 2025.
  • Its 3-year average for EBIT is -$36.6 million, with a median of -$38.2 million in 2024.
  • Per our database at Business Quant, Caribou Biosciences' EBIT tumbled by 607.94% in 2021 and then spiked by 44.86% in 2023.
  • Quarterly analysis of 5 years shows Caribou Biosciences' EBIT stood at -$20.4 million in 2021, then plummeted by 49.86% to -$30.6 million in 2022, then declined by 22.45% to -$37.4 million in 2023, then fell by 3.83% to -$38.9 million in 2024, then increased by 23.11% to -$29.4 million in 2025.
  • Its EBIT was -$29.4 million in Q3 2025, compared to -$47.6 million in Q2 2025 and -$42.9 million in Q1 2025.